129263-68-9

Upstream product

• 67-56-1 methanol 
• 532-20-7 D-Ribose 
• 77-76-9 2,2-dimethoxy-propane 
• 36468-53-8 β-D-ribofuranose 
• 67-64-1 acetone 
• 144732-43-4 (3aR,6R,6aR)-4-Methoxy-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 532-20-7 D-lyxose 
• 50-69-1 D-ribose 
• 1824-96-0 methyl ribofuranoside 
• 10257-32-6 D-ribose 
• 87-72-9 D-lyxose 
• 1114-34-7 D-lyxose 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 98807-30-8 N⁴-Benzoyl-1-(2,3-O-isopropylidene-α-D-ribofuranosyl)-cytosine 
• 39946-94-6 4-N-benzoyl-2',3'-O-isopropylidenecytidine 
• 268545-16-0 5-O-benzoyl-2,3-isopropylidene-1-methoxy-D-ribofuranoside 
• 4137-56-8 ((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 
• 144993-84-0 methyl 5,6-didehydro-5,6-dideoxy-2,3-O-isopropylidene-D-allofuranoside 
• 114817-96-8 (4S,5R)-2,2-dimethyl-4-hydroxymethyl-5-vinyl-1,3-dioxolane 
• 683276-44-0 (4R,5S)-4,5-O-isopropylidenecyclopenten-1-ol 
• 27821-07-4 1,2,3-tri-O-acetyl-5-deoxy-β-D-ribofuranose 
• 161599-46-8 (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyl-tetrahydrofuran-3,4-diyl diacetate 
• 162204-20-8 N¹-(2',3'-di-O-acetyl-5'-deoxy-β-D-ribofuranosyl)-5-fluoro-N⁴-(pentyloxycarbonyl)cytosine 
• 154361-50-9 capecitabine 
• 1101174-62-2 (6S,7R,7aS)-6,7-dihydroxy-tetrahydro-pyrrolo[1,2-c]oxazol-3-one 
• 87-72-9 L-arabinofuranose 
• 279673-09-5 (2R,3R,4S,5R)-5-methyltetrahydrofuran-2,3,4-triol 

Relevant academic research and scientific papers

A general synthesis of specifically deuterated nucleotides for studies of DNA and RNA

An efficient procedure is described for the preparation of ribonucleotides and deoxyribonucleotides with deuterium incorporated at the 1′, 4′, or 5′ position. Three intermediates-[1-2H]-D-ribose, [4-2H]-D-ribose, and [5-2H

In situ characterization of advanced glycation end products (AGEs) in collagen and model extracellular matrix by solid state NMR

Non-enzymatic glycation of extracellular matrix with (U-13C5)-d-ribose-5-phosphate (R5P), enables in situ 2D ssNMR identification of many deleterious protein modifications and crosslinks, including previously unreported oxalamido and

Synthesis of N-alkyl substituted iminosugars from D-ribose

An effective and facile method for the synthesis of N-alkylated hydroxylpyrrolidine and hydroxylpiperidine is described. A number of N-alkyl substituted iminosugars were prepared using iodine-induced intramolecular cyclization of acyclic alkenylamines as key step.

Formal synthesis of (-)-oleocanthal by means of a SmI2-promoted intramolecular coupling of bromoalkyne with α,β-unsaturated ester

A novel approach to the synthesis of (-)-oleocanthal starting from d-ribose, in which a SmI2-promoted intramolecular coupling of bromoalkyne with α,β-unsaturated ester is a key step, has been developed.

MEAYAMYCIN ANALOGUES AND METHODS OF USE

Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Preparation method of ticagrelor key intermediate iodide

The invention discloses a preparation method of ticagrelor key intermediate iodide, which comprises the following steps of: (1) synthesis of an intermediate 1: taking D-ribose as a raw material, methanol and acetone as solvents, adding thionyl chloride as a catalyst, and concentrating to remove the solvents after the reaction is finished, so as to obtain the intermediate 1, and (3) synthesis of the key intermediate iodide: by taking acetonitrile as a solvent, adding the intermediate 1 and sodium iodide into a reaction system, dropwise adding trimethylchlorosilane, adding a small amount of water for quenching reaction after the reaction is finished, evaporating to remove acetonitrile, extracting with the solvent, and concentrating to obtain the key intermediate iodide. According to the preparation method of the ticagrelor key intermediate iodide, in the synthesis process of the intermediate 1, thionyl chloride is adopted to replace hydrochloric acid to serve as a catalyst, the reactionconversion rate is greatly increased, then trimethylchlorosilane/sodium iodide serves as an iodinating agent, the reaction condition is mild, aftertreatment is simple, and the conversion rate is high.

Total Synthesis of Meayamycin and O-Acyl Analogues

A short, scalable total synthesis of meayamycin is described by an approach that entails a longest linear sequence of 12 steps (22 steps overall) from commercially available chiral pool materials (ethyl l-lactate, BocNH-Thr-OH, and d-ribose) and introduces the most straightforward preparation of the right-hand subunit detailed to date. The use of the approach in the divergent synthesis of a representative series of O-acyl analogues is exemplified.

Industrial large-scale production method of capecitabine intermediate

The invention provides an industrial large-scale production method of a capecitabine intermediate. The industrial large-scale production method adopts a one-pot production method of simultaneously adding methanol and acetone, and is a preparation method which is energy-saving, short in production period and high in yield; a method of adding low-boiling-point solvents such as ethyl acetate into dimethyl sulfoxide or pyrrolidone for reflux cooling to take away heat is adopted; and a production method of hydrolyzing while distilling is designed, the methanol and the acetone which are generated byhydrolysis are distilled out, the methanol and the acetone in water are continuously reduced, the reaction is carried out towards K3, and the reaction is complete and thorough.

Tumor immunity compound and application thereof

Disclosed are a tumor immunity compound and an application thereof. The invention discloses a compound as shown in the formula (I), optical isomers thereof, and pharmaceutically acceptable salts thereof, and an application of the compound as an STING agonist.